Ignite Creation Date:
2024-05-06 @ 3:06 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04529863
Status:
COMPLETED
Last Update Posted:
2021-11-16
First Post:
2020-08-25
Brief Title:
Data Analysis for Drug Repurposing for Effective Alzheimers Medicines DREAM - Tocilizumab vs Abatacept
Sponsor:
Brigham and Womens Hospital
Organization:
Brigham and Womens Hospital
Study Overview
Official Title:
Data Analysis for Drug Repurposing for Effective Alzheimers Medicines- Tocilizumab vs Abatacept
Status:
COMPLETED
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DREAM
Brief Summary:
This study aims to evaluate the comparative risk of dementiaAlzheimers disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication
Detailed Description:
This is a non-randomized non-interventional study that is part of the DREAM Study of Brigham and Womens Hospital DREAM is led by Dr Madhav Thambisetty MD PhD Chief of the Clinical and Translational Neuroscience Section Laboratory of Behavioral Neuroscience National Institute on Aging NIA intramural research program This study aims to evaluate the comparative risk of dementiaAlzheimers disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 75N95019C00057 | OTHER_GRANT | National Institute on Aging | None |